Evidence map›Paper›PMID 21908429›Full record

ReviewBlood2011

Mast cell modulation of the vascular and lymphatic endothelium.

Christian A Kunder, Ashley L St John, Soman N Abraham

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02673840 (Ketotifen as a Treatment for Vascular Leakage During Dengue Fever), which is not on this map. Cited by 130 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02673840 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)

TypeinterventionalSponsorNational University Hospital, SingaporeRan2015 to 2017Enrolled110ConditionsDengue Fever, Pleural EffusionArmsKetotifen, Placebo
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 1 synthesis or guideline pooled it, 212 citations in OpenAlex.

  1. Immunology of heart failure with preserved ejection fraction.Expert review of clinical immunology · 2025
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Mast Cells in the Developing Brain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Platelet-mast cell dialogue in innate immune response and inflammation.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  14. Article
  15. Review
  16. Role of Cellular Mechanisms in Dengue Pathogenesis: Focus on Immune Cells Interactions.Combinatorial chemistry & high throughput screening · 2026
    Review
  17. Innate Immune and Inflammatory Responses to Dengue Virus Infection.Current topics in microbiology and immunology · 2026
    Review
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Christian A KunderDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Ashley L St John
Soman N Abraham
Duke Medical Center · US

Funding

Development of Efficacious and Stable Nasal Vaccine FormulationsU01AI082107 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2009 to 2013
$3.8M
Caveolae Mediated Bacterial Uptake in the Urinary TractR01AI050021 · NIAID · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2001 to 2010
$3.6M
Modulation of Bladder cAMP to combat UTI'sR01DK077159 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2007 to 2011
$1.7M
Development of Efficacious Vaccine Against UTI'sR21DK077307 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2008 to 2010
$529k
Nasal adjuvant to enhance anti-cocaine vaccinesR21DA029731 · NIDA · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, STAATS, HERMAN F · 2011 to 2012
$432k
NIAID NIH HHS R01 AI050021NIAID NIH HHS R01 AI50021NIAID NIH HHS U01 AI082107NIAID NIH HHS U01AI082107NIDA NIH HHS R21 DA029731NIDDK NIH HHS R01 DK077159NIDDK NIH HHS R21 DK077307
6 · The paper itself

Abstract

Mast cells (MCs) promote a wide range of localized and systemic inflammatory responses. Their involvement in immediate as well as chronic inflammatory reactions at both local and distal sites points to an extraordinarily powerful immunoregulatory capacity with spatial and temporal versatility. MCs are preferentially found in close proximity to both vascular and lymphatic vessels. On activation, they undergo a biphasic secretory response involving the rapid release of prestored vasoactive mediators followed by de novo synthesized products. Many actions of MCs are related to their capacity to regulate vascular flow and permeability and to the recruitment of various inflammatory cells from the vasculature into inflammatory sites. These mediators often work in an additive fashion and achieve their inflammatory effects locally by directly acting on the vascular and lymphatic endothelia, but they also can affect distal sites. Along these lines, the lymphatic and endothelial vasculatures of the host act as a conduit for the dissemination of MC signals during inflammation. The central role of the MC-endothelial cell axis to immune homeostasis is emphasized by the fact that some of the most effective current treatments for inflammatory disorders are directed at interfering with this interaction.

Indexed as

AnimalsEndothelium, LymphaticEndothelium, VascularHomeostasisHumansImmunomodulationInflammationMast Cells

Identifiers

PMID21908429
PMCPMC3217344
OpenAlexW2091439605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.